<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Hematol</journal-id><journal-id journal-id-type="iso-abbrev">Int J Hematol</journal-id><journal-title-group><journal-title>International Journal of Hematology</journal-title></journal-title-group><issn pub-type="ppub">0925-5710</issn><issn pub-type="epub">1865-3774</issn><publisher><publisher-name>Springer Nature Singapore</publisher-name><publisher-loc>Singapore</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39903436</article-id><article-id pub-id-type="pmc">PMC11861407</article-id>
<article-id pub-id-type="publisher-id">3911</article-id><article-id pub-id-type="doi">10.1007/s12185-024-03911-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Successful treatment of type I cryoglobulinemia with a combination of carfilzomib, cyclophosphamide, and dexamethasone: a case report and literature review</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yasuda</surname><given-names>Yohei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Maki</surname><given-names>Hiroaki</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shimura</surname><given-names>Arika</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Honda</surname><given-names>Akira</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Masamoto</surname><given-names>Yosuke</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4034-2422</contrib-id><name><surname>Kurokawa</surname><given-names>Mineo</given-names></name><address><email>kurokawa@m.u-tokyo.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/057zh3y96</institution-id><institution-id institution-id-type="GRID">grid.26999.3d</institution-id><institution-id institution-id-type="ISNI">0000 0001 2169 1048</institution-id><institution>Department of Hematology and Oncology, Graduate School of Medicine, </institution><institution>The University of Tokyo, </institution></institution-wrap>7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655 Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/022cvpj02</institution-id><institution-id institution-id-type="GRID">grid.412708.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1764 7572</institution-id><institution>Department of Cell Therapy and Transplantation Medicine, </institution><institution>The University of Tokyo Hospital, </institution></institution-wrap>7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655 Japan </aff></contrib-group><pub-date pub-type="epub"><day>4</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>4</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>121</volume><issue>3</issue><fpage>411</fpage><lpage>415</lpage><history><date date-type="received"><day>30</day><month>7</month><year>2024</year></date><date date-type="rev-recd"><day>21</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>24</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Type I cryoglobulinemia is typically associated with hematological malignancies such as B-cell lymphomas and plasma cell neoplasms. Its treatment basically targets underlying hematological malignancies, and the prognosis remains unsatisfactory. Despite several reports of type I cryoglobulinemia treated with bortezomib-based regimens, little is available on the treatment of bortezomib-resistant cases. We report a case of severe type I cryoglobulinemia associated with plasma cell neoplasm, refractory to bortezomib and daratumumab, which was successfully managed with a combination of carfilzomib, cyclophosphamide, and dexamethasone (KCd therapy). No sign of relapse has been seen for more than 3&#x000a0;years with maintenance therapy with ongoing carfilzomib. This case highlights the potential efficacy of carfilzomib-based regimens in bortezomib-resistant type I cryoglobulinemia, offering a promising option for cases refractory to conventional treatments.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Type I cryoglobulinemia</kwd><kwd>Plasma cell neoplasm</kwd><kwd>Carfilzomib</kwd><kwd>Cyclophosphamide</kwd></kwd-group><funding-group><award-group><funding-source><institution>The University of Tokyo</institution></funding-source></award-group><open-access><p>Open Access funding provided by The University of Tokyo.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Japanese Society of Hematology 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Cryoglobulinemia is characterized by specific antibodies in the blood that aggregate or precipitate at low (&#x0003c;&#x02009;37 &#x02103;) temperatures, leading to inflammation and damage in small blood vessels [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Type II and type III cryoglobulinemia, where cryoglobulins are composed of polyclonal immunoglobulins (typically IgG) with or without monoclonal immunoglobulins (typically IgM with rheumatoid factor activity), are mainly caused by inflammatory conditions, with chronic hepatitis C virus (HCV) infection being the most common, followed by other infectious diseases and autoimmune disorders [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. In type I cryoglobulinemia, on the other hand, cryoglobulins are monoclonal immunoglobulins basically produced by hematological malignancies, including B-cell lymphomas such as lymphoplasmacytic lymphoma/Waldenstr&#x000f6;m&#x02019;s macroglobulinemia (20&#x02013;33%), as well as plasma cell neoplasms such as multiple myeloma (11&#x02013;20%) and monoclonal gammopathy of undetermined significance (31&#x02013;44%) [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. Symptoms of type I cryoglobulinemia are primarily related to vessel obstruction and inflammation, presenting as skin lesions (28&#x02013;86%) with necrosis occurring frequently (10&#x02013;28%), Raynaud&#x02019;s syndrome (13&#x02013;31%), joint pain (13&#x02013;28%), kidney involvement (14&#x02013;35%), and peripheral neuropathy (14&#x02013;44%) [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par3">While the treatment of cryoglobulinemia basically targets underlying hematological malignancies, the prognosis of type I cryoglobulinemia remains poor. According to the data from the past five cohorts, the 10-year overall survival rates ranged from 52.5 to 68%, except for the study by Terrier et al. that reported a higher rate of 87% [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par4">Cohort studies and case reports indicate that bortezomib-based regimens have been used for type I cryoglobulinemia associated with plasma cell tumors [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. However, the literature on the treatment of bortezomib-resistant cases is scarce. Herein, we report a case of bortezomib-resistant type I cryoglobulinemia related to plasma cell neoplasm successfully treated with a regimen comprising carfilzomib, cyclophosphamide, and dexamethasone (KCd therapy) [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>].</p></sec><sec id="Sec2"><title>Case presentation</title><p id="Par5">A 77-year-old man presented to an outpatient dermatology clinic primarily concerned with skin rashes that persisted for about a year, mainly on his knees, feet, and hands. Some lesions on his feet exhibited minor skin changes suggestive of ischemia. Skin biopsies were performed from a purpura on the feet and an erythema on the hand, revealing numerous fibrin thrombi within small vessels and intravascular inflammatory findings, indicative of leukocytoclastic vasculitis. Regarding vascular risk factors, the patient was an ex-smoker with a history of 20 pack-years and had no history of hypertension, diabetes, or hyperlipidemia. Blood tests showed an elevated IgG level (4208&#x000a0;mg/dl) with other immunoglobulin classes near the lower limits of normal, along with cryoglobulinemia (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). Autoimmune and viral serologies, including hepatitis C, were negative. Immunofixation electrophoresis (IFE) identified two bands of IgG-&#x003bb; type, indicating aggregation of cryoglobulin (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). The bone marrow examination revealed 3.8% of plasma cells with CD38&#x02009;+&#x02009;, CD19&#x02212;, and light chain restriction to lambda, suggesting an abnormal plasma cell population. These findings indicated type I cryoglobulinemia. Upon PET-CT evaluation, no evidence of lymphadenopathy, hepatic or splenic involvement, or other extramedullary manifestations was detected.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>A comparative visualization of cryoclots and serum immunofixation electrophoresis at diagnosis and post-treatment. B Timeline of the clinical progression and treatment interventions. <italic>IFE</italic> immunofixation electrophoresis, <italic>PE</italic> plasma exchange, <italic>FLC</italic> free light chain</p></caption><graphic xlink:href="12185_2024_3911_Fig1_HTML" id="MO1"/></fig></p><p id="Par6">Immunosuppressive therapies, including methylprednisolone pulse therapy (1000&#x000a0;mg/day, 3&#x000a0;days) followed by oral prednisone, high-dose cyclophosphamide (500&#x000a0;mg/m<sup>2</sup>), and weekly rituximab (375&#x000a0;mg/m<sup>2</sup>) for 4&#x000a0;weeks, were initially applied by the Dermatology department, ending in a modest reduction in the IgG level to 2005&#x000a0;mg/dl.</p><p id="Par7">A few months later, the patient was emergently hospitalized due to a high fever and subsequently transferred to our department. There was no clinical, laboratory, or imaging evidence of infection. Severe progression of skin necrosis suggested exacerbation of cryoglobulinemia-associated vasculitis. Re-elevation of the IgG level (4,238&#x000a0;mg/dl) prompted the initiation of plasma exchange therapy to reduce cryoglobulins. The bone marrow examination revealed 10% CD138-positive plasma cells in the marrow clot section, while the smear showed 9%. These findings fulfill the diagnostic criteria for multiple myeloma, with anemia serving as a myeloma-defining event.</p><p id="Par8">As causative therapy, we initiated Vd therapy with doses adjusted for frailty comprising bortezomib (1.0&#x000a0;mg/m<sup>2</sup>) and dexamethasone (20&#x000a0;mg/body) on days 1, 8, and 15 of a 28-day cycle [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. The use of immunomodulatory drugs was precluded by deep vein thrombosis detected on ultrasound examination. Despite the initiation of this therapy, there was a gradual increase in IgG levels. Bone marrow aspiration performed 20&#x000a0;days after treatment initiation revealed 11% plasma cells, indicating a lack of response to the therapy. We added weekly daratumumab (16&#x000a0;mg/kg), transitioning to DVd therapy [<xref ref-type="bibr" rid="CR19">19</xref>] and escalated bortezomib to 1.3&#x000a0;mg/m<sup>2</sup> to intensify treatment, while maintaining a 28-day cycle. Although the regimen moderately reduced serum IgG levels and temporarily made cryoclots undetectable during the first two cycles, a recurrence in IgG levels and the reappearance of cryoclots was observed during the subsequent two cycles. The progression of skin necrosis, particularly in the knees and feet, persisted, leading us to prepare for above-knee amputation of both legs. We altered the regimen to KCd therapy in unfit doses, comprising carfilzomib (36&#x000a0;mg/m<sup>2</sup>), cyclophosphamide (150&#x000a0;mg/m<sup>2</sup>) administered on days 1, 8, and 15 of a 28-day cycle with weekly dexamethasone (20&#x000a0;mg/body) [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Cyclophosphamide was included to enhance therapeutic efficacy, as dose escalation of carfilzomib was limited by frailty and immunomodulatory drugs were contraindicated due to persistent deep vein thrombosis. It quickly decreased serum IgG levels and eliminated cryoglobulins, enabling discontinuation of plasma exchange therapy. The ischemic lesions showed marked improvement. The necrosis in the lesions below the ankles had already progressed to an irreversible stage, still requiring amputation. However, as the blood flow in the knees had improved, the amputation was performed below the knees on both lower limbs. As a representative indicator of the necrotic lesions, the time-series images of the knee lesions are illustrated in the clinical chart (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b).</p><p id="Par9">Nine cycles in total were completed without severe non-hematological toxicity. With the subsequent ongoing carfilzomib maintenance, no progression of symptoms or re-emergence of cryoclots has been detected for over 3&#x000a0;years, while IFE remained positive for IgG-&#x003bb; throughout the entire clinical course.</p></sec><sec id="Sec3"><title>Discussion</title><p id="Par10">In the present case, KCd (carfilzomib, cyclophosphamide, and dexamethasone) therapy achieved rapid and long-lasting remission in a patient with bortezomib-refractory type I cryoglobulinemia associated with a plasma cell neoplasm. Even with the inclusion of bortezomib in plasma cell neoplasms cases, the most recent cohort showed that the 5-year event-free survival rate for IgG type I cryoglobulinemia remains low at just 8% [<xref ref-type="bibr" rid="CR9">9</xref>]. The present case was especially challenging, suggesting a considerably poor prognosis, as the patient showed total refractoriness to initial VD (bortezomib and dexamethasone) therapy. However, the introduction of KCd therapy demonstrated remarkable efficacy in overcoming bortezomib resistance in our case.</p><p id="Par11">One of the most striking features of this case was the rapidity with which cryoglobulins disappeared and symptoms improved. This remarkable outcome suggested strong selectivity of carfilzomib for cryoglobulin-producing clones. The persistent detection of M protein despite the complete elimination of cryoglobulins further supports this hypothesis, considering the heterogeneity of the disease. Carfilzomib, an irreversible and specific inhibitor of chymotrypsin-like activities of proteasomes [<xref ref-type="bibr" rid="CR20">20</xref>], might particularly challenge these clones with the production of especially abnormal globulins.</p><p id="Par12">This case highlights the difficulties in managing type I cryoglobulinemia. Although immunosuppressive therapies including rituximab are commonly used for symptomatic relief [<xref ref-type="bibr" rid="CR7">7</xref>], expert opinions recommend prioritizing treatment of underlying malignancies, as mentioned in the introduction section [<xref ref-type="bibr" rid="CR2">2</xref>]. In our case, the initial approach of immunosuppressive therapy, chosen due to low tumor burden, resulted in rapid progression of vasculitis, reinforcing the importance of proactive initiation of chemotherapy.</p><p id="Par13">The concept of &#x0201c;Monoclonal gammopathy of clinical significance&#x0201d; (MGCS), including type I cryoglobulinemia, has been recently proposed[<xref ref-type="bibr" rid="CR21">21</xref>], in which even small amounts of monoclonal proteins can cause significant clinical symptoms. The decision to initiate polychemotherapy for underlying malignancies should be promptly determined based on the patient&#x02019;s symptomatic presentation rather than on quantitative parameters of tumor burden or cryoglobulin levels. In light of this concept, the presented case suggests that progressing necrotic lesions may serve as an indicator for proactive therapeutic intervention. Furthermore, prompt salvage therapies should be considered even in cases where first-line therapies partially improve cryoglobulin levels.</p><p id="Par14">To clarify the result of previous studies on type I cryoglobulinemia, clinical manifestations and the prognoses are summarized in a table (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. The studies share many common findings, notably the high prevalence of MGUS as an underlying disease. This prevalence of MGUS is significant as it suggests that even a small number of tumor cells can lead to the development of the disease. Regarding symptoms, skin lesions are frequently reported, with a notable incidence of necrosis. Moreover, except for the study by Terrier et al., these studies generally report a poor long-term prognosis. The study by Ghembaza et al. analyzed prognosis based on underlying disorders and Ig type, showing inferior outcomes for IgG type, along with higher incidence of necrosis and renal failure [<xref ref-type="bibr" rid="CR9">9</xref>].<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Summary of major cohorts of type I cryoglobulinemia</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study</th><th align="left">Terrier 2013</th><th align="left">Harel 2014</th><th align="left">N&#x000e9;el 2014</th><th align="left">Sidana 2017</th><th align="left">Ghembaza 2023</th></tr><tr><th align="left">Nation</th><th align="left">France</th><th align="left">France</th><th align="left">France</th><th align="left">US</th><th align="left">France</th></tr></thead><tbody><tr><td align="left" colspan="6">Characteristics</td></tr><tr><td align="left">&#x000a0;Number of patients</td><td align="left">64</td><td align="left">64</td><td align="left">36</td><td align="left">102</td><td align="left">168</td></tr><tr><td align="left">&#x000a0;Median age (years)</td><td align="left">65</td><td align="left">62</td><td align="left">63</td><td align="left">59</td><td align="left">65</td></tr><tr><td align="left">&#x000a0;IgG type (%)</td><td align="left">N/A</td><td align="left">60</td><td align="left">31</td><td align="left">53</td><td align="left">45</td></tr><tr><td align="left" colspan="6">Hematological malignancy (%)</td></tr><tr><td align="left">&#x000a0;MGUS</td><td align="left">44</td><td align="left">41</td><td align="left">36</td><td align="left">38</td><td align="left">31</td></tr><tr><td align="left">&#x000a0;MM</td><td align="left">19</td><td align="left">19</td><td align="left">11</td><td align="left">20</td><td align="left">15</td></tr><tr><td align="left">&#x000a0;LPL</td><td align="left">20</td><td align="left">28</td><td align="left">33</td><td align="left">21</td><td align="left">27</td></tr><tr><td align="left">&#x000a0;Other B-cell lymphomas</td><td align="left">17</td><td align="left">13</td><td align="left">19</td><td align="left">14</td><td align="left">7</td></tr><tr><td align="left" colspan="6">Symptoms (%)</td></tr><tr><td align="left">&#x000a0;Skin manifestations</td><td align="left">86</td><td align="left">58</td><td align="left">58</td><td align="left">63</td><td align="left"><p><bold>IgG: 45</bold></p><p>IgM: 15</p></td></tr><tr><td align="left">&#x000a0;Necrosis</td><td align="left">28</td><td align="left"><p><bold>IgG: 37</bold></p><p>IgM: 7.7</p></td><td align="left"><p><bold>IgG: 55</bold></p><p>IgM: 8</p></td><td align="left">34</td><td align="left"><p><bold>IgG: 18</bold></p><p>IgM: 3</p></td></tr><tr><td align="left">&#x000a0;Renal involvement</td><td align="left">30</td><td align="left"><p><bold>IgG: 29</bold></p><p>IgM: 7.7</p></td><td align="left">22</td><td align="left">14</td><td align="left"><p><bold>IgG: 54</bold></p><p>IgM: 19</p></td></tr><tr><td align="left">&#x000a0;Raynaud syndrome</td><td align="left">N/A</td><td align="left">19</td><td align="left">31</td><td align="left">25</td><td align="left">13</td></tr><tr><td align="left">&#x000a0;Joint arthralgia</td><td align="left">28</td><td align="left">N/A</td><td align="left">19</td><td align="left">24</td><td align="left">13</td></tr><tr><td align="left">&#x000a0;Peripheral neuropathy</td><td align="left">44</td><td align="left">14</td><td align="left">39</td><td align="left">32</td><td align="left">20</td></tr><tr><td align="left" colspan="6">Prognosis</td></tr><tr><td align="left">&#x000a0;5-year PFS (%)</td><td align="left">N/A</td><td align="left">28</td><td align="left">N/A</td><td align="left">N/A</td><td align="left"><p><bold>IgG: 8</bold></p><p>IgM: 47</p></td></tr><tr><td align="left">&#x000a0;5-year OS (%)</td><td align="left">94</td><td align="left">83</td><td align="left">82</td><td align="left">N/A</td><td align="left">77</td></tr><tr><td align="left">&#x000a0;10-year OS (%)</td><td align="left">87</td><td align="left">68</td><td align="left">60</td><td align="left">Median OS: 11.4&#x000a0;years</td><td align="left"><p><bold>IgG: 36</bold></p><p>IgM: 71</p></td></tr></tbody></table><table-wrap-foot><p>Bold values indicate&#x000a0;significant differences (<italic>p&#x02009;&#x0003c;</italic>&#x02009;0.05) between IgG and IgM types</p><p>For the N&#x000e9;el [<xref ref-type="bibr" rid="CR10">10</xref>] and Sidana [<xref ref-type="bibr" rid="CR7">7</xref>] studies, the &#x02018;Necrosis&#x02019; category includes both necrosis and ulcers</p><p><italic>MGUS</italic> monoclonal gammopathy of undetermined significance, <italic>MM</italic> multiple myeloma, <italic>LPL</italic> lymphoplasmacytic lymphoma, <italic>PFS</italic> progression-free survival, <italic>OS</italic> overall survival</p></table-wrap-foot></table-wrap></p><p id="Par15">Regarding novel therapies including bortezomib and/or immunomodulators, high response rates have been reported, although long-term efficacy remains limited. In the study by Sidana et al., ten of twelve patients experienced symptom relief [<xref ref-type="bibr" rid="CR7">7</xref>]. For IgG-type cryoglobulinemia, the study by Ghembaza et al. reports complete symptom relief in 6&#x000a0;months in 60&#x02013;100% of patients. However, the 5-year event-free survival (EFS) rate for IgG-type patients, of whom 39% were treated with bortezomib, was only 8% in the same cohort [<xref ref-type="bibr" rid="CR9">9</xref>]. Given the persistently high incidence of relapse, it is considered necessary to explore treatment options for relapsed or refractory cases. Nevertheless, studies reporting effective treatments for bortezomib-resistant cases are scarce. It appears crucial to accumulate cases and knowledge regarding salvage therapies, especially those using emerging drugs such as other PIs and molecular targeted drugs such as anti-CD38 monoclonal antibody. The present case provides important insights in this context, despite the limitations of being a single case report with a limited observation period. In addition, the possibility that the dose reduction of bortezomib due to frailty compromised its efficacy should be considered as a limitation in interpreting the resistance to bortezomib.</p><p id="Par16">In conclusion, this case report demonstrates the remarkable efficacy of a carfilzomib-based therapy in achieving rapid and long-lasting remission in bortezomib-refractory type I cryoglobulinemia associated with a plasma cell neoplasm. This finding is particularly significant given the scarcity of reports on effective treatments for bortezomib-resistant cases in the literature. Although further validation through the accumulation of additional cases and large-scale studies is necessary, carfilzomib-based regimens appear to be a promising therapeutic approach for this challenging clinical scenario.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors are grateful to the patient and the medical staff involved for their contributions to this case report.</p></ack><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding provided by The University of Tokyo.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data that support the findings of this case report are available upon reasonable request, subject to privacy and ethical restrictions.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par17">Yosuke Masamoto: honoraria, Janssen Pharmaceutical K.K., CHUGAI PHARMACEUTICAL CO., LTD. Mineo Kurokawa: research funding, Takeda Pharmaceutical Company Limited, CHUGAI PHARMACEUTICAL CO., LTD.; honoraria, Janssen Pharmaceutical K.K., Amgen Inc., Takeda Pharmaceutical Company Limited, CHUGAI PHARMACEUTICAL CO., LTD.; Editor of International Journal of Hematology.</p></notes><notes id="FPar2"><title>Informed consent</title><p id="Par18">Informed consent was obtained from the patient for publication of this case report and accompanying images.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Desbois</surname><given-names>AC</given-names></name><name><surname>Cacoub</surname><given-names>P</given-names></name><name><surname>Saadoun</surname><given-names>D</given-names></name></person-group><article-title>Cryoglobulinemia: an update in 2019</article-title><source>Joint Bone Spine</source><year>2019</year><volume>86</volume><fpage>707</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1016/j.jbspin.2019.01.016</pub-id><pub-id pub-id-type="pmid">30731128</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Desbois AC, Cacoub P, Saadoun D. Cryoglobulinemia: an update in 2019. Joint Bone Spine. 2019;86:707&#x02013;13.<pub-id pub-id-type="pmid">30731128</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Muchtar</surname><given-names>E</given-names></name><name><surname>Magen</surname><given-names>H</given-names></name><name><surname>Gertz</surname><given-names>MA</given-names></name></person-group><article-title>How I treat cryoglobulinemia</article-title><source>Blood</source><year>2017</year><volume>129</volume><fpage>289</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-09-719773</pub-id><pub-id pub-id-type="pmid">27799164</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Muchtar E, Magen H, Gertz MA. How I treat cryoglobulinemia. Blood. 2017;129:289&#x02013;98.<pub-id pub-id-type="pmid">27799164</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos-Casals</surname><given-names>M</given-names></name><name><surname>Stone</surname><given-names>JH</given-names></name><name><surname>Cid</surname><given-names>MC</given-names></name><name><surname>Bosch</surname><given-names>X</given-names></name></person-group><article-title>The cryoglobulinaemias</article-title><source>Lancet</source><year>2012</year><volume>379</volume><fpage>348</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(11)60242-0</pub-id><pub-id pub-id-type="pmid">21868085</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Ramos-Casals M, Stone JH, Cid MC, Bosch X. The cryoglobulinaemias. Lancet. 2012;379:348&#x02013;60.<pub-id pub-id-type="pmid">21868085</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferri</surname><given-names>C</given-names></name></person-group><article-title>Mixed cryoglobulinemia</article-title><source>Orphanet J Rare Dis</source><year>2008</year><volume>3</volume><fpage>25</fpage><pub-id pub-id-type="doi">10.1186/1750-1172-3-25</pub-id><pub-id pub-id-type="pmid">18796155</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Ferri C. Mixed cryoglobulinemia. Orphanet J Rare Dis. 2008;3:25.<pub-id pub-id-type="pmid">18796155</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Roccatello</surname><given-names>D</given-names></name><name><surname>Saadoun</surname><given-names>D</given-names></name><name><surname>Ramos-Casals</surname><given-names>M</given-names></name><name><surname>Tzioufas</surname><given-names>AG</given-names></name><name><surname>Fervenza</surname><given-names>FC</given-names></name><name><surname>Cacoub</surname><given-names>P</given-names></name><etal/></person-group><article-title>Cryoglobulinaemia</article-title><source>Nat Rev Dis Primers</source><year>2018</year><volume>4</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1038/s41572-018-0009-4</pub-id><pub-id pub-id-type="pmid">30072738</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Roccatello D, Saadoun D, Ramos-Casals M, Tzioufas AG, Fervenza FC, Cacoub P, et al. Cryoglobulinaemia. Nat Rev Dis Primers. 2018;4:11.<pub-id pub-id-type="pmid">30072738</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Harel</surname><given-names>S</given-names></name><name><surname>Mohr</surname><given-names>M</given-names></name><name><surname>Jahn</surname><given-names>I</given-names></name><name><surname>Aucouturier</surname><given-names>F</given-names></name><name><surname>Galicier</surname><given-names>L</given-names></name><name><surname>Asli</surname><given-names>B</given-names></name><etal/></person-group><article-title>Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases</article-title><source>Br J Haematol</source><year>2015</year><volume>168</volume><fpage>671</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1111/bjh.13196</pub-id><pub-id pub-id-type="pmid">25363150</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Harel S, Mohr M, Jahn I, Aucouturier F, Galicier L, Asli B, et al. Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases. Br J Haematol. 2015;168:671&#x02013;8.<pub-id pub-id-type="pmid">25363150</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Sidana</surname><given-names>S</given-names></name><name><surname>Rajkumar</surname><given-names>SV</given-names></name><name><surname>Dispenzieri</surname><given-names>A</given-names></name><name><surname>Lacy</surname><given-names>MQ</given-names></name><name><surname>Gertz</surname><given-names>MA</given-names></name><name><surname>Buadi</surname><given-names>FK</given-names></name><etal/></person-group><article-title>Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia</article-title><source>Am J Hematol</source><year>2017</year><volume>92</volume><fpage>668</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1002/ajh.24745</pub-id><pub-id pub-id-type="pmid">28370486</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Sidana S, Rajkumar SV, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, et al. Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. Am J Hematol. 2017;92:668&#x02013;73.<pub-id pub-id-type="pmid">28370486</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Terrier</surname><given-names>B</given-names></name><name><surname>Karras</surname><given-names>A</given-names></name><name><surname>Kahn</surname><given-names>JE</given-names></name><name><surname>Le Guenno</surname><given-names>G</given-names></name><name><surname>Marie</surname><given-names>I</given-names></name><name><surname>Benarous</surname><given-names>L</given-names></name><etal/></person-group><article-title>The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases</article-title><source>Medicine (Baltimore)</source><year>2013</year><volume>92</volume><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1097/MD.0b013e318288925c</pub-id><pub-id pub-id-type="pmid">23429354</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Terrier B, Karras A, Kahn JE, Le Guenno G, Marie I, Benarous L, et al. The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases. Medicine (Baltimore). 2013;92:61&#x02013;8.<pub-id pub-id-type="pmid">23429354</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Ghembaza</surname><given-names>A</given-names></name><name><surname>Boleto</surname><given-names>G</given-names></name><name><surname>Bommelaer</surname><given-names>M</given-names></name><name><surname>Karras</surname><given-names>A</given-names></name><name><surname>Javaugue</surname><given-names>V</given-names></name><name><surname>Bridoux</surname><given-names>F</given-names></name><etal/></person-group><article-title>Prognosis and long-term outcomes in type I cryoglobulinemia: a multicenter study of 168 patients</article-title><source>Am J Hematol</source><year>2023</year><volume>98</volume><fpage>1080</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1002/ajh.26944</pub-id><pub-id pub-id-type="pmid">37139676</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Ghembaza A, Boleto G, Bommelaer M, Karras A, Javaugue V, Bridoux F, et al. Prognosis and long-term outcomes in type I cryoglobulinemia: a multicenter study of 168 patients. Am J Hematol. 2023;98:1080&#x02013;6.<pub-id pub-id-type="pmid">37139676</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>N&#x000e9;el</surname><given-names>A</given-names></name><name><surname>Perrin</surname><given-names>F</given-names></name><name><surname>Decaux</surname><given-names>O</given-names></name><name><surname>Dejoie</surname><given-names>T</given-names></name><name><surname>Tessoulin</surname><given-names>B</given-names></name><name><surname>Halliez</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long-term outcome of monoclonal (type 1) cryoglobulinemia</article-title><source>Am J Hematol</source><year>2014</year><volume>89</volume><fpage>156</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1002/ajh.23608</pub-id><pub-id pub-id-type="pmid">24532335</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">N&#x000e9;el A, Perrin F, Decaux O, Dejoie T, Tessoulin B, Halliez M, et al. Long-term outcome of monoclonal (type 1) cryoglobulinemia. Am J Hematol. 2014;89:156&#x02013;61.<pub-id pub-id-type="pmid">24532335</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Payet</surname><given-names>J</given-names></name><name><surname>Livartowski</surname><given-names>J</given-names></name><name><surname>Kavian</surname><given-names>N</given-names></name><name><surname>Chandesris</surname><given-names>O</given-names></name><name><surname>Dupin</surname><given-names>N</given-names></name><name><surname>Wallet</surname><given-names>N</given-names></name><etal/></person-group><article-title>Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature</article-title><source>Leuk Lymphoma</source><year>2013</year><volume>54</volume><fpage>767</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.3109/10428194.2012.671481</pub-id><pub-id pub-id-type="pmid">22385269</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Payet J, Livartowski J, Kavian N, Chandesris O, Dupin N, Wallet N, et al. Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature. Leuk Lymphoma. 2013;54:767&#x02013;77.<pub-id pub-id-type="pmid">22385269</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Besada</surname><given-names>E</given-names></name><name><surname>Vik</surname><given-names>A</given-names></name><name><surname>Koldingsnes</surname><given-names>W</given-names></name><name><surname>Nossent</surname><given-names>JC</given-names></name></person-group><article-title>Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review</article-title><source>Int J Hematol</source><year>2013</year><volume>97</volume><fpage>800</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1007/s12185-013-1323-y</pub-id><pub-id pub-id-type="pmid">23616220</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Besada E, Vik A, Koldingsnes W, Nossent JC. Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review. Int J Hematol. 2013;97:800&#x02013;3.<pub-id pub-id-type="pmid">23616220</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Bringhen</surname><given-names>S</given-names></name><name><surname>Petrucci</surname><given-names>MT</given-names></name><name><surname>Larocca</surname><given-names>A</given-names></name><name><surname>Conticello</surname><given-names>C</given-names></name><name><surname>Rossi</surname><given-names>D</given-names></name><name><surname>Magarotto</surname><given-names>V</given-names></name><etal/></person-group><article-title>Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study</article-title><source>Blood</source><year>2014</year><volume>124</volume><fpage>63</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-03-563759</pub-id><pub-id pub-id-type="pmid">24855212</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Bringhen S, Petrucci MT, Larocca A, Conticello C, Rossi D, Magarotto V, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124:63&#x02013;9.<pub-id pub-id-type="pmid">24855212</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Puertas</surname><given-names>B</given-names></name><name><surname>Gonz&#x000e1;lez-Calle</surname><given-names>V</given-names></name><name><surname>Sureda</surname><given-names>A</given-names></name><name><surname>Moreno</surname><given-names>MJ</given-names></name><name><surname>Oriol</surname><given-names>A</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>E</given-names></name><etal/></person-group><article-title>Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients</article-title><source>Haematologica</source><year>2023</year><volume>108</volume><fpage>2753</fpage><lpage>2763</lpage><pub-id pub-id-type="doi">10.3324/haematol.2022.282490</pub-id><pub-id pub-id-type="pmid">37102598</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Puertas B, Gonz&#x000e1;lez-Calle V, Sureda A, Moreno MJ, Oriol A, Gonz&#x000e1;lez E, et al. Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients. Haematologica. 2023;108:2753&#x02013;63.<pub-id pub-id-type="pmid">37102598</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Yong</surname><given-names>K</given-names></name><name><surname>Hinsley</surname><given-names>S</given-names></name><name><surname>Sherratt</surname><given-names>D</given-names></name><name><surname>Kendall</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>SR</given-names></name><name><surname>Flanagan</surname><given-names>L</given-names></name><etal/></person-group><article-title>Carfilzomib versus bortezomib in combination with cyclophosphamide and dexamethasone for treatment of first relapse or primary refractory multiple myeloma (MM): outcomes based on genetic risk and long term follow up of the phase 2 Muk five study</article-title><source>Blood</source><year>2018</year><volume>132</volume><fpage>306</fpage><pub-id pub-id-type="doi">10.1182/blood-2018-99-116624</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Yong K, Hinsley S, Sherratt D, Kendall J, Brown SR, Flanagan L, et al. Carfilzomib versus bortezomib in combination with cyclophosphamide and dexamethasone for treatment of first relapse or primary refractory multiple myeloma (MM): outcomes based on genetic risk and long term follow up of the phase 2 Muk five study. Blood. 2018;132:306.</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Harousseau</surname><given-names>JL</given-names></name><name><surname>Attal</surname><given-names>M</given-names></name><name><surname>Leleu</surname><given-names>X</given-names></name><name><surname>Troncy</surname><given-names>J</given-names></name><name><surname>Pegourie</surname><given-names>B</given-names></name><name><surname>Stoppa</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study</article-title><source>Haematologica</source><year>2006</year><volume>91</volume><fpage>1498</fpage><lpage>1505</lpage><pub-id pub-id-type="pmid">17043025</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006;91:1498&#x02013;505.<pub-id pub-id-type="pmid">17043025</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Mikhael</surname><given-names>JR</given-names></name><name><surname>Belch</surname><given-names>AR</given-names></name><name><surname>Prince</surname><given-names>HM</given-names></name><name><surname>Lucio</surname><given-names>MN</given-names></name><name><surname>Maiolino</surname><given-names>A</given-names></name><name><surname>Corso</surname><given-names>A</given-names></name><etal/></person-group><article-title>High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program</article-title><source>Br J Haematol</source><year>2009</year><volume>144</volume><fpage>169</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2008.07409.x</pub-id><pub-id pub-id-type="pmid">19036114</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, et al. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol. 2009;144:169&#x02013;75.<pub-id pub-id-type="pmid">19036114</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Larocca</surname><given-names>A</given-names></name><name><surname>Palumbo</surname><given-names>A</given-names></name></person-group><article-title>How I treat fragile myeloma patients</article-title><source>Blood</source><year>2015</year><volume>126</volume><fpage>2179</fpage><lpage>2185</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-05-612960</pub-id><pub-id pub-id-type="pmid">26324701</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Larocca A, Palumbo A. How I treat fragile myeloma patients. Blood. 2015;126:2179&#x02013;85.<pub-id pub-id-type="pmid">26324701</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Sonneveld</surname><given-names>P</given-names></name><name><surname>Chanan-Khan</surname><given-names>A</given-names></name><name><surname>Weisel</surname><given-names>K</given-names></name><name><surname>Nooka</surname><given-names>AK</given-names></name><name><surname>Masszi</surname><given-names>T</given-names></name><name><surname>Beksac</surname><given-names>M</given-names></name><etal/></person-group><article-title>Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label</article-title><source>Phase III Trial J Clin Oncol</source><year>2023</year><volume>41</volume><fpage>1600</fpage><lpage>1609</lpage><pub-id pub-id-type="pmid">36413710</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Sonneveld P, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label. Phase III Trial J Clin Oncol. 2023;41:1600&#x02013;9.<pub-id pub-id-type="pmid">36413710</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Demo</surname><given-names>SD</given-names></name><name><surname>Kirk</surname><given-names>CJ</given-names></name><name><surname>Aujay</surname><given-names>MA</given-names></name><name><surname>Buchholz</surname><given-names>TJ</given-names></name><name><surname>Dajee</surname><given-names>M</given-names></name><name><surname>Ho</surname><given-names>MN</given-names></name><etal/></person-group><article-title>Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>6383</fpage><lpage>6391</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-4086</pub-id><pub-id pub-id-type="pmid">17616698</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67:6383&#x02013;91.<pub-id pub-id-type="pmid">17616698</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Fermand</surname><given-names>J-P</given-names></name><name><surname>Bridoux</surname><given-names>F</given-names></name><name><surname>Dispenzieri</surname><given-names>A</given-names></name><name><surname>Jaccard</surname><given-names>A</given-names></name><name><surname>Kyle</surname><given-names>RA</given-names></name><name><surname>Leung</surname><given-names>N</given-names></name><etal/></person-group><article-title>Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications</article-title><source>Blood</source><year>2018</year><volume>132</volume><fpage>1478</fpage><lpage>1485</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-04-839480</pub-id><pub-id pub-id-type="pmid">30012636</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Fermand J-P, Bridoux F, Dispenzieri A, Jaccard A, Kyle RA, Leung N, et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132:1478&#x02013;85.<pub-id pub-id-type="pmid">30012636</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>